Depression: A Global Public Health Concern

Marcus, Mildred Rendl; Mt, Yasamy; Chisholm, Daniel; Saxena, Sumit; Yasamy, M. Taghi; m, Van Ommeren; Ommeren, Mark van; Chrisholm, D. J

doi:10.1037/e517532013-004

Cited by 496 publications

(357 citation statements)

References 0 publications

Supporting

Mentioning

328

Contrasting

Unclassified

Order By: Relevance

“…Also carriers of the C allele represented 3.3 fold better response to sertraline comparing with other variants (P=0.001, OR=3.3; 95%CI=1.72-6.50). While world-wide rate of depression is rapidly increasing (36), response to antidepressants and remission is fairly satisfactory (37). Although many studies bold the contribution of genetics in predisposition to MDD, its role as therapeutic determinant remains obscure.…”

Section: Discussionmentioning

confidence: 99%

Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

et al. 2017

View full text Add to dashboard Cite

-Purpose: The adrenoceptor family, as one of the main contributors in regulating the noradrenergic system, has been studied in involvement of depression and its treatment. A functional polymorphism of G1165C on beta adrenoceptor (βAR) enhances post receptor signalling and is assumed to be involved in pharmacotherapy of depression. The aim of the present study was to discern the influence of G1165C polymorphism in the β1AR gene on individual differences in response to sertraline. Methods: One hundred newly diagnosed patients completed 6 weeks of sertraline treatment. Response to treatment was defined as a 50% decrease in Hamilton Rating Scale for depression (HRSD). Results: The patients who carried CC genotype responded five times more to sertraline comparing with other variants (P=0.005; OR=5.7; 95%CI=1.4-23.9). Moreover, carriers of C allele responded three times more to sertraline than patients with the G allele (P=0.001; OR= 3.3; 95%CI= 1.72-6.50). Conclusion:In conclusion, our results support the hypothesis that genetic variation of β1AR might influence clinical response to sertraline.

show abstract

Section: Discussionmentioning

confidence: 99%

Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…We assume that the paralysis of the injected frown muscles interrupts a proprioceptive feedback loop from the face to the emotional brain, therefore reducing the ability to feel negative emotions [15][16][17]. In depression, there is a Introduction ▼ Affecting more than 350 million individuals worldwide, depression is one of the greatest medical challenges of our time [1]. There are several effective psychotherapeutic, pharmacological, and somatic options for the treatment of depression, but still a considerable proportion of patients do not attain remission.…”

mentioning

confidence: 99%

Treating Depression with Botulinum Toxin: A Pooled Analysis of Randomized Controlled Trials

Magid

Finzi²,

Krüger

et al. 2015

Pharmacopsychiatry

View full text Add to dashboard Cite

Introduction: Botulinum toxin A (BTA) injection into the glabellar region is currently being studied as a treatment for major depressive disorder (MDD). Here we explore efficacy data of this novel approach in a pooled analysis. Methods: A literature search revealed 3 RCTs on this topic. Individual patient data and clinical end points shared by these 3 trials were pooled and analyzed as one study (n=134) using multiple regression models with random effects. Results: In the pooled sample, the BTA (n=59) and the placebo group (n=75) did not differ in the baseline variables. Efficacy outcomes revealed BTA superiority over placebo: Improvement in the Hamilton Depression Rating Scale or Montgomery-Asberg Depression Rating Scale 6 weeks after baseline was 45.7% for BTA vs. 14.6% for placebo (p<0.0001), corresponding to a BTA response rate of 54.2% (vs. 10.7%) and a BTA remission rate of 30.5% (vs. 6.7%). Discussion: Equalling the status of a meta-analysis, this study increases evidence that a single treatment of BTA into the glabellar region can reduce symptoms of MDD. Further studies are needed to better understand how BTA exerts its mood-lifting effect.

show abstract

“…Depression, if detected early, could save the healthcare system millions of dollars. Depression has been described as the common cold of mental health, and the rates of depression around the world appear to be worsening (Marcus et al, 2012). More research needs to be conducted to determine the influence depression has on developing diabetes.…”

Section: Conclusion Limitations and Recommendationsmentioning

confidence: 99%

An Analysis of Depression and Diabetes amongst African American Women

Cooke

O’Lawrence

2017

European Journal of Environment and Public Health

View full text Add to dashboard Cite

This study determined the level of depression and the rate of diabetes among the adult African American female population. By identifying the population early, one can save millions of dollars, improve health outcomes, and treat depression that typically interferes with diabetes management. The study used secondary data from the 2011-2012 California Health Interview Survey. The 2011-2012 CHIS surveyed 42,935 adults and of those surveyed 1,403 respondents identified themselves as African Americans. Chisquare analysis was used to determine the strength of the association between diabetes in African American women with depression and exercise. The results of the statistical tests show that there was an association between the independent variables suggesting a statistically significant relationship in African American women. A major limitation of the study was the small number of African Americans interviewed in the survey. A larger sample size at the national level is recommended to more closely scrutinize the directional nature of the relationship between diabetes and depression in African American women.

show abstract

Depression: A Global Public Health Concern

Cited by 496 publications

References 0 publications

Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

Treating Depression with Botulinum Toxin: A Pooled Analysis of Randomized Controlled Trials

An Analysis of Depression and Diabetes amongst African American Women

Contact Info

Product

Resources

About